Wis., discusses his priorities for the newly created Make America Healthy Again caucus amid the Trump administraton’s mass ...

Following a lackluster 2024, shares of major drug markers kicked off 2025 with an upbeat quarterly results reading.

US aid freeze affects HIV and malaria supply chains, FDA postpones rare disease events, and a leap in Texas measles cases. Meanwhile, Mirum Pharma's drug gets FDA approval, Eli Lilly invests in a ...

Much to the Democrats’ chagrin, Robert F. Kennedy Jr. is now the United States’ new Health and Human Services secretary.

The Make America Healthy Again movement had a negative impact on pharmaceutical innovation and the corporations responsible for it.

Persistently high rates of both type 1 and 2 diabetes as well as racial health disparities are indicators of lingering gaps in care for Indigenous communities.

With Trump in office and Republicans controlling Congress, it’s time for the president to continue work he started and ...

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

President Donald Trump will meet with major drugmakers' executives to discuss drug pricing and insurance changes. Key topics ...

Calley Means, advisor to RFK Jr. locked horns with CNN anchor Pamela Brown and called out an alleged big pharma shill in real ...

Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.

Vaccine policy, Medicare drug negotiations, and a potential DTC advertising ban will all fall under Kennedy’s purview as HHS Secretary.